Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Fred Hutch researchers present progress in treating metastatic cancer with novel therapies, including a Phase II study testing TNF-a inhibitors for castration-resistant prostate cancer. The center also explores improving hospice access and using machine learning with CAR T-cell therapy to enhance patient outcomes.
A recent study uses AI to analyze body composition in patients with lung cancer treated with immunotherapy, finding that changes in muscle mass and fat quality are important indicators of outcomes. The research provides a more nuanced understanding of the relationship between body composition and response to immunotherapy.
A novel gene cluster expression analysis was introduced to potentially expand treatments for more lung cancer patients. The study found that a gene cluster expression index can classify cancers with dramatically different recurrence risks, with higher risk groups suitable for targeted therapy or immunotherapy.
Researchers from Mount Sinai will present new research on long COVID, lung cancer, asthma, and sleep apnea at the ATS 2024 International Conference. The studies aim to improve diagnosis and care for these conditions.
A new study by University of Liverpool researchers demonstrates that lung cancer screening offers comparable benefits to all socioeconomic groups, reducing deaths from COPD and emphysema. The study highlights the importance of targeted screening programs for disadvantaged populations.
A nationwide cohort study found that ex-smokers who vape after quitting cigarettes are at a higher risk of developing lung cancer and dying from it. The study analyzed over 4 million individuals and categorized them into six groups based on their smoking history and habit change.
A Phase III study found that perioperative nivolumab plus chemotherapy significantly improved event-free survival in patients with resectable early-stage non-small cell lung cancer. The treatment also showed higher rates of pathological complete response and major pathological response compared to chemotherapy alone.
New cancer projections highlight progress in reducing incidence rates for common cancers like lung, colorectal, and prostate, but also warn of rising rates for less common types such as liver, kidney, melanoma, and non-Hodgkin lymphoma.
Researchers have developed a breakthrough therapy that can adapt CAR-T cell therapy to target solid tumors, potentially transforming cancer treatment. The therapy uses a novel antibody and costimulatory protein to activate T cells, overcoming the challenges of immune suppression in solid tumors.
A late University of Virginia School of Medicine scientist's research on the SAS1B protein could lead to new cancer treatments for multiple cancers. The discovery has the potential to selectively target cancer cells while sparing healthy tissue.
The prevalence of lung cancer mutations varies significantly across different ethnic groups in Latin America, highlighting the need for region-specific medical interventions. Enhancing molecular diagnostic and research efforts is crucial for effective management of cancer in this population.
A study published by University of Pittsburgh researchers found that ACA insurance expansions led to an increase in patients receiving care at accredited cancer hospitals in Pennsylvania. The study suggests that these expansions make a difference in improving access to high-quality cancer care, particularly for those living in areas wi...
Research shows breast cancer survivors are at increased risk of developing second cancers, including endometrial and ovarian cancer for women, and prostate cancer for men. Socioeconomic deprivation is linked to a greater risk of second cancers among breast cancer survivors.
Researchers identified elevated MALAT1 levels in various blood cancers, correlating with adverse outcomes. MALAT1 promotes cancer cell proliferation, migration, invasion, and metastasis through multiple mechanisms.
A new study found that offering stop smoking support alongside lung cancer screening can significantly increase quit rates among high-risk individuals. Up to half of those who attend for lung cancer screening currently smoke, and dedicated funding is urged to provide this essential support.
Researchers at H. Lee Moffitt Cancer Center & Research Institute discovered a new therapeutic target for non-small cell lung cancer by targeting the Jagged2 protein. Disrupting this signaling pathway activates anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages.
Scientists at German Cancer Research Center have discovered a combination therapy that improves treatment response and delays resistance in lung cancer cells. The therapy, which combines ALK and SRC inhibitors, blocks key protein expression changes that lead to resistance.
A new study developed two machine learning models to quantify CD8+ cell positivity and classify the immunophenotype of cancer specimens in patients with non-small cell lung cancer. The models hold promise for identifying patients who may benefit from immunotherapy.
Tetracycline antibiotics have been found to enhance the antitumor activity of T lymphocytes by targeting galactin-1, an immunosuppressive protein produced by cancer cells. This breakthrough discovery may lead to the development of new drugs that target different immune pathways and benefit patients with cancer.
A new lab assay developed by Fred Hutch Cancer Center researchers detects differences between types of lung cancer using patterns in cell-free tumor DNA. The blood-based test has the potential to classify clinical subtypes driven by transcriptional programs and expand treatment selection for patients with small-cell lung cancer.
The study assessed relationships between TCM syndromes and lung cancer TNM staging indicators, finding phlegm dampness syndrome dominant in stages I & II, Qi Yin deficiency syndrome in stages III & IV. The findings suggest bias in included literature, emphasizing the need for larger sample sizes and clinical experimental investigations.
A population-wide observational study found an association between tuberculosis (TB) and a higher incidence of various cancers. TB patients were more likely to be diagnosed with lung, blood, gynaecological, colorectal, thyroid, oesophagus, and stomach cancers compared to the general population.
A clinical trial from Keck Medicine of USC will investigate the feasibility of treating non-small cell lung cancer with immunotherapy provided at home. The study aims to enroll 37 patients and examine the safety, efficacy, and patient compliance with at-home treatment.
Researchers outline ferroptosis mechanisms and regulatory networks in lung cancer, highlighting potential therapeutic targets. The study suggests ferroptosis as a novel approach to overcome treatment resistance in lung cancer, providing hope for improving clinical outcomes.
A Mount Sinai study found that primary care physicians' approach to selecting patients with comorbidities for lung cancer screening is influenced by subjective clinical judgments. The researchers recommend streamlined protocols and clearer guidelines to increase adoption of lung cancer screening for this high-risk population.
A new therapy combines gene-modified dendritic cells with immunotherapy to promote a stronger immune response against lung cancer. The treatment slows down tumor growth and activates T cells to attack cancer cells systemically.
Primary care physicians struggle to balance harms and benefits of lung cancer screening in patients with multiple health issues, often relying on clinical judgment. Ultimately, the decision rests with the patient, who makes their own choice despite physician advice.
Patients with multimorbidity and limited life expectancy are often unaware of the potential harms of lung cancer screening. Despite this, many agree to undergo screening due to personal health goals, trust in their clinician, and anticipation of regret over not getting screened. Discussions between patients and clinicians about the ben...
Developed by scientists from the University of Oxford, the LungVax vaccine uses technology similar to the highly successful Oxford/AstraZeneca COVID-19 vaccine. The vaccine will train the immune system to recognise and attack abnormal lung cells with neoantigens.
Researchers have identified a crucial interface in a mutated protein that drives lung cancer growth, which could act as a target for more effective treatments. The study used advanced laser imaging techniques to provide unprecedented details of the protein's structure and interactions.
A new study from Johns Hopkins Medicine found that circulating tumor DNA levels can accurately assess how gastroesophageal cancers respond to treatment and predict future prognosis. The study tracked minimal residual disease by analyzing ctDNA, showing a correlation between ctDNA clearance and cancer-free survival.
Researchers at Massachusetts General Hospital have discovered a network of immune cells, called stem-immunity hubs, that are associated with a favorable response to immunotherapy in non-small cell lung cancer. The presence of these hubs can serve as a biomarker to predict response to treatment.
Researchers propose combining osimertinib with gefitinib to increase progression-free survival rates in EGFR-mutant lung cancer patients. A comprehensive PC approach could dramatically boost PFS for 80% of patients, eliminating harm and improving treatment outcomes.
A study by Cancer Research UK reveals that mortality rates have dropped by 37% in men and 33% in women, with significant reductions in cervical cancer and lung cancer. However, cancer cases are on the rise overall, and researchers warn of an immense challenge ahead to maintain progress.
Scientists at Johns Hopkins have developed a novel approach to identify cancer-causing repeats in DNA sequences, enabling non-invasive detection and monitoring of cancers. The ARTEMIS method uses machine learning to analyze cell-free DNA and distinguish between tumor and normal tissues with high accuracy.
Researchers found that patients recovering from robotic lung surgery do not fully recover even after 90 days, despite common expectations. The study suggests a more thoughtful approach to pre-surgery communication with patients is needed to better understand their recovery experiences.
Researchers discovered that lung cancer cells can persist in the presence of cigarette smoke due to a protein pump called ABCG2, which clears damaging molecules from the cells. This mechanism could also contribute to resistance to pharmaceutical treatments in cancer cells.
Researchers analyzed access to new treatments for early-stage lung cancer in Europe, highlighting existing disparities in healthcare systems and reimbursement structures. The study calls for a collective European approach to reduce inequalities in access to care.
A large-scale study has found a significant link between smoking and DNA methylation, with two new epigenetic markers identified that differ by race or ethnicity. The research could lead to better ways to predict smoking-related disease risk and improve early detection and treatment.
Researchers at the University of Pennsylvania have developed a new method to efficiently determine which lipid nanoparticles are likely to bind to the lungs, rather than the liver. This breakthrough enables targeted delivery of mRNA therapeutics beyond the liver, offering new hope for treatments of cystic fibrosis and lung cancer.
Researchers at University at Buffalo propose a new approach to developing cancer drugs by determining the optimal placement of molecular linkers earlier in the process, reducing trial and error and increasing potency, according to a study published in Communications Chemistry.
A new atlas of lung cells reveals transitional alveolar cell state harboring KRAS mutations in normal lung cells, which can lead to lung adenocarcinoma. This finding opens doors for developing new detection strategies.
Researchers found elevated radon gas levels in rural homes near drilled groundwater wells, with a 30% higher exposure risk compared to urban areas. Regular testing is crucial for mitigating radon-related lung cancer risks in rural communities.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
A new genetic signature of 140 genes may predict enhanced disease-free survival in patients with non-small cell lung cancer treated with immunotherapy and low-dose radiation. The signature is associated with aggressive tumor growth but also increased immunity and tissue repair after treatment.
Researchers found that Inuit residents in Nunavik had shorter survival rates for lung cancer compared to Montreal residents, despite similar disease stages. The study attributes this disparity to chronic under-resourcing of healthcare services and lack of Inuit representation in healthcare provision.
Researchers identify a promising prognostic biomarker for lung cancer using circulating tumor DNA-based minimal residual disease detection. The study found that this method can effectively guide treatment decisions and predict recurrence risk, potentially modifying the lung cancer treatment paradigm.
A new study has identified a genetic marker that can predict which patients are likely to respond to immunotherapy in various types of cancer. Tumors with high intragenic rearrangement (IGR) burden, which indicates cryptic structural rearrangements of the genetic code, may respond better to immunotherapy.
A Phase II trial found that durvalumab plus ceralasertib provided the greatest clinical benefit in patients with immunotherapy-resistant non-small cell lung cancer, with improved overall survival and objective response rates. The combination showed a manageable safety profile.
Lung adenocarcinoma cells manipulate macrophage lipid metabolism to drive tumor progression. This exploitation of immune cells' metabolic pathways may be targeted with statins, improving lung cancer treatments.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
The research group evaluated the on- and off-target effects of a self-assembled EGFR siRNA delivery system, finding potent interference with only 1/2000000 of synthetic transfection amount. Transcriptomic analysis revealed minimal off-target effects in normal tissues and significant anti-EGFR effects in tumor cells.
A study of 2.9 million Korean adults found that quitting smoking at any age reduced the risk of cancer, particularly lung cancer, after 10 years. Early cessation before middle age led to a substantial risk reduction in lung cancer.
A new study found an association between radon exposure and an increased risk of stroke in middle-aged female participants. The study showed that even moderate concentrations of radon were linked to a higher risk of stroke compared to those exposed to lower concentrations.
Cancer kills more Black people than White individuals in the Barretos region, whereas in São Paulo city, it is the opposite, according to a study published in Cancer Causes & Control. The disparity is most pronounced for breast and cervical cancer among Black women.
Researchers developed a new chip that can detect cancer cells in blood samples, enabling clinicians to adapt treatments and improve outcomes for patients with lung cancer. The device traps and concentrates tiny numbers of cancer cells, allowing for regular monitoring of treatment effectiveness.
Experts predict a significant increase in bowel cancer death rates among young adults in the EU and UK, driven by rising obesity and heavy alcohol consumption. Death rates are predicted to rise by 26% in men and nearly 39% in women in the UK, with similar increases seen in Italy and other European countries.
Researchers report a case of a patient with EGFR L858R mutant non-small cell lung cancer (NSCLC) who experienced durable disease improvement after empirical treatment with osimertinib. The 'Lazarus effect' refers to the phenomenon where cancer appears to recur after seeming to be in remission.
A study from Dana-Farber Cancer Institute found that unintentional weight loss is associated with an increased risk of cancer diagnosis within the coming year. The research suggests that patients experiencing unexpected weight loss should see their doctor to consider possible causes, including cancer. Healthy weight loss can come from ...